Sarcopenia Market Expected to Grow at a CAGR of 10.6% Through 2034

The sarcopenia treatment market is valued at approximately USD 2.3 billion in 2025 and is projected to grow at a significant CAGR of 10.6% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the sarcopenia landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The sarcopenia market is increasingly guided by emerging therapeutic approaches. Biophytis' Sarconeos (BIO101), a natural bioactive compound designed to improve muscle function, represents a highly promising therapeutic option. TNF Pharmaceuticals' Isomyosamine, a selective TNF inhibitor candidate, is also advancing through the clinical development pipeline with strong safety profiles.

Sarcopenia, an age-related condition impacting approximately 15% of older adults and closely linked to frailty, affects a significant patient population. The total diagnosed prevalent cases of sarcopenia in the 7MM were 20 million in 2024. In the United States, sarcopenia prevalence increases substantially with age, with individuals aged 65 and older representing the majority of affected patients. The condition demonstrates higher prevalence rates in men compared to women, and shows greater occurrence in rural populations than urban areas, reflecting socioeconomic and lifestyle disparities in disease burden.

DelveInsight's report, "Sarcopenia Market Insights, Epidemiology and Market Forecast-2034," provides a comprehensive analysis of the sarcopenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines sarcopenia market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the sarcopenia market outlook, drug uptake, treatment scenario and epidemiology trends, click here: Sarcopenia Market Forecast

Key Facts of the Sarcopenia Market Report

• Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, Dong Wha PHARM, and others
• Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others
• The sarcopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage sarcopenia pipeline products will significantly revolutionize the sarcopenia market dynamics. Rising healthcare expenditure, improving diagnostic capabilities, and growing focus on healthy aging initiatives further support market expansion.

Sarcopenia Overview

Sarcopenia is a progressive age-related condition characterized by the loss of skeletal muscle mass, strength, and function. It develops due to a misalignment of signals for muscle cell growth and breakdown, resulting in reduced quality of life, increased risk of fractures, falls, disability, and frailty. The condition represents a significant clinical and public health challenge, particularly among older adults, and is increasingly recognized as an independent predictor of adverse health outcomes and mortality.

Key Trends in Sarcopenia Therapeutics Market

• Emerging Pharmacological Interventions: Growing development of novel oral agents targeting muscle metabolism and inflammatory pathways, including selective TNF inhibitors and myostatin pathway modulators.
• Integrated Treatment Approaches: Increased recognition of the need to combine pharmacological treatments with nutritional support and exercise programs for comprehensive management.
• Biomarker-Driven Development: Enhanced focus on identifying and utilizing biomarkers such as inflammatory cytokines (TNF-α, IL-6) to guide patient selection and treatment optimization.
• Nutritional Therapeutic Expansion: Growing emphasis on protein supplementation, amino acid formulations, and targeted dietary interventions as integral components of sarcopenia management.
• Digital Health Integration: Development of remote monitoring technologies and digital platforms to support patient adherence and track muscle function outcomes.
• Precision Medicine Applications: Advancement toward personalized treatment strategies based on patient phenotypes, genetic factors, and comorbid conditions such as obesity and chronic inflammation.

Sarcopenia Epidemiology

The report on sarcopenia epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on sarcopenia severity classifications. The report also highlights risk factors, disease burden and projections for future trends help stakeholders understand the scope of sarcopenia and plan targeted interventions, research, and treatment strategies.

Sarcopenia Epidemiology Segmentation

The sarcopenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total diagnosed prevalent cases of sarcopenia
• Gender-specific diagnosed prevalent cases of sarcopenia
• Age-specific diagnosed prevalent cases of sarcopenia
• Severity-specific diagnosed prevalent cases of sarcopenia

Download the report to understand which factors are driving sarcopenia epidemiology trends at Sarcopenia Epidemiology Forecast

Recent Developments in the Sarcopenia Treatment Landscape

• January 2025: TNF Pharmaceuticals, Inc. announced completion of a 13-week FDA-recommended safety study demonstrating that isomyosamine is safe at all tested doses. This milestone enables expanded and longer clinical trials, with the company planning to initiate a Phase 2b trial in early 2025 to evaluate isomyosamine's efficacy in treating sarcopenia and frailty. The company is also preparing additional studies examining isomyosamine's potential to address muscle loss and inflammation associated with GLP-1 medications.
• December 2024: Epirium Bio, Inc. announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for ES-1602, advancing the company's sarcopenia pipeline development.
• April 2025: TNF Pharmaceuticals presented platform data on isomyosamine for the treatment of sarcopenia in older adults at the British Geriatrics Society (BGS) Spring Meeting 2025, held in Belfast, Ireland.
• Ongoing Phase 3 Development: Biophytis continues advancing Sarconeos (BIO101) in the SARA-31 phase 3 study, the first-ever phase 3 clinical trial in sarcopenia. Approximately 900 patients over 65 years of age with severe sarcopenia are being enrolled to evaluate the efficacy and safety of BIO101 administered at 350mg twice daily. The primary endpoint assesses the risk of major mobility disability, with secondary endpoints including walking speed, handgrip strength, and patient-reported quality-of-life measures.

Sarcopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of adoption of potential drugs recently launched in the sarcopenia market or expected to get launched during the study period. The analysis covers sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers sarcopenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sarcopenia Therapies and Key Companies

• MYMD-1/Isomyosamine: TNF Pharmaceuticals
• LPCN 1148: Lipocine
• Sarconeos (BIO101): Biophytis
• Froniglutide (PF-1801): Pfizer
• RJx-01: Rejuvenate Biomed
• KER-065: Keros Therapeutics
• BPM 31510 (ubidecarenone): BPGbio, Inc.
• OC514: Oncocross
• MT29: Mirscience Therapeutics
• TRN-005: Turn Biotechnologies
• NMDP-05: NMD PHARMA
• PF1807: ImmunoForge
• DW1030: Dong Wha PHARM

To know more about sarcopenia companies working in the treatment market, visit Sarcopenia Clinical Trials and Therapeutic Assessment

Sarcopenia Market Drivers

• Increasing prevalence of sarcopenia globally, driven by aging populations and improved diagnostic awareness
• Growth of targeted pharmacological therapies addressing underlying sarcopenia mechanisms
• Advancements in biomarker identification and validation enabling precision medicine approaches
• Rising healthcare expenditure and government initiatives supporting age-related disease management
• Expanding awareness through screening programs and clinical guidelines
• Development of combination therapies improving patient outcomes and functional capacity
• Integration of sarcopenia assessment into routine geriatric healthcare practices
• Growing recognition of sarcopenia's impact on healthcare costs and patient quality of life

Sarcopenia Market Barriers

• Limited availability of FDA-approved pharmacological treatments for sarcopenia
• Complex diagnostic criteria requiring specialized muscle function assessments
• High cost of emerging therapies limiting patient access in some regions
• Insufficient reimbursement coverage in multiple healthcare systems
• Patient compliance challenges with long-term therapeutic regimens
• Variability in disease presentation and treatment response across patient populations
• Geographic disparities in diagnostic and therapeutic resources
• Perception of lifestyle interventions as adequate substitutes for pharmacological treatment

Scope of the Sarcopenia Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, Dong Wha PHARM, and others
• Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others
• Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and emerging therapies
• Sarcopenia Market Dynamics: Sarcopenia market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Sarcopenia Unmet Needs, KOL's Views, Analyst's Views, Sarcopenia Market Access and Reimbursement

Discover more about therapies set to grab major sarcopenia market share at the Sarcopenia Treatment Market